Aurobindo Pharma Ltd

Ola Electric Mobility Ltd, Aster DM Healthcare Ltd, Data Patterns (India) Ltd and Shilpa Medicare Ltd are among the other losers in the BSE's 'A' group today, 15 June 2026.Aurobindo Pharma Ltd lost 4.55% to Rs 1405.3 at 14:47 IST.The stock was the biggest loser in the BSE's 'A' group.On the BSE, 55749 shares were traded on the counter so far as against the average daily volumes of 50382 shares in the past one month.Ola Electric Mobility Ltd tumbled 3.96% to Rs 43.92. The stock was the second biggest loser in 'A' group.On the BSE, 66.22 lakh shares were traded on the counter so far as against the average daily volumes of 125.03 lakh shares in the past one month.Aster DM Healthcare Ltd crashed 3.15% to Rs 789.25. The stock was the third biggest loser in 'A' group.On the BSE, 42723 shares were traded on the counter so far as against the average daily volumes of 62252 shares in the past one month.Data Patterns (India) Ltd pared 3.03% to Rs 4407.8. The stock was the fourth biggest loser in 'A' group.On the BSE, 71819 shares were traded on the counter so far as against the average daily volumes of 79760 shares in the past one month.Shilpa Medicare Ltd dropped 2.52% to Rs 532.45. The stock was the fifth biggest loser in 'A' group.On the BSE, 45035 shares were traded on the counter so far as against the average daily volumes of 73771 shares in the past one month.Powered by Capital Market - Live

The inspection was carried out at Eugia Unit-III, a formulation manufacturing facility operated by Eugia Pharma Specialities, a wholly owned subsidiary of Aurobindo Pharma, located in Pashamylaram, Telangana. The USFDA conducted the inspection between 27 January to 6 February 2026. At the conclusion of the inspection, the regulator had issued 11 observations to the facility. The company has now informed stock exchanges that the US FDA has determined the inspection classification status as OAI. Aurobindo Pharma is engaged in the manufacturing and marketing of active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services. The company reported a 2% rise in consolidated net profit to Rs 921.26 crore on a 4.4% increase in net sales to Rs 8,751.50 crore in Q4 FY26 over Q4 FY25. Powered by Capital Market - Live

The inspection was carried out at Eugia Unit-III, a formulation manufacturing facility operated by Eugia Pharma Specialities, a wholly owned subsidiary of Aurobindo Pharma, located in Pashamylaram, Telangana. The USFDA conducted the inspection between 27 January to 6 February 2026. At the conclusion of the inspection, the regulator had issued 11 observations to the facility. The company has now informed stock exchanges that the US FDA has determined the inspection classification status as OAI. Aurobindo Pharma is engaged in the manufacturing and marketing of active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services. The company reported a 2% rise in consolidated net profit to Rs 921.26 crore on a 4.4% increase in net sales to Rs 8,751.50 crore in Q4 FY26 over Q4 FY25. The counter rose 0.56% closed at Rs 1,472.25 on the BSE on Friday. Powered by Capital Market - Live

The product is bioequivalent and therapeutically equivalent to the reference listed drug, Xeljanz Tablets, of PF Prism C.V. It will be manufactured at APL Healthcare Unit IV, a wholly owned subsidiary of the company, and is scheduled for immediate launch. According to IQVIA MAT data for the 12 months ended April 2026, the US market for Tofacitinib tablets is estimated at approximately $494 million. Following this approval, Aurobindo Pharma has a total of 586 ANDA approvals from the USFDA, comprising 561 final approvals and 25 tentative approvals. Tofacitinib tablets are indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis, active psoriatic arthritis, and moderately to severely active ulcerative colitis, specifically in cases where patients have had an inadequate response or intolerance to prior standard therapies such as methotrexate or other disease-modifying antirheumatic drugs. In ulcerative colitis, the use also applies to patients who have not responded adequately or are intolerant to TNF (tumour necrosis factor) blockers. Separately, the company inaugurated TheraNym, its dedicated biologics contract manufacturing organization (CMO), marking its entry into the biologics contract manufacturing segment. Located at Borapatla near Hyderabad, the facility is positioned as one of India's largest dedicated biologics CMOs. Aurobindo Pharma said MSD (known as Merck & Co. in the US and Canada) will serve as the anchor customer for the facility, which has been established to support domestic and export supply requirements, subject to applicable approvals and customer requirements. Aurobindo Pharma is engaged in the manufacturing and marketing of active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services. The company reported a 2% rise in consolidated net profit to Rs 921.26 crore on a 4.4% increase in net sales to Rs 8,751.50 crore in Q4 FY26 over Q4 FY25.Powered by Capital Market - Live

Aurobindo Pharma has received a final approval from the US Food & Drug Administration (USFDA) to manufacture and market Tofacitinib Tablets, 5 mg and 10 mg, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Xeljanz Tablets, 5 mg and 10 mg, of PF Prism C.V. The product will be manufactured at APL Healthcare Unit IV, a wholly owned subsidiary of the company and will be launched immediately.

Aurobindo Pharma announced that the United States Food and Drug Administration (US FDA) inspected Unit-I, a formulation manufacturing facility, of Eugia Pharma Specialities, a wholly owned subsidiary of the Company, situated at Kolthur Village, Shameerpet Mandal, Ranga Reddy, 500078, Telangana, from February 16 to February 27, 2026. The inspection had concluded with 4 observations. FDA has now determined that the inspection classification of this facility is 'official action indicated' (OAI).

Net profit of Aurobindo Pharma rose 1.97% to Rs 921.26 crore in the quarter ended March 2026 as against Rs 903.47 crore during the previous quarter ended March 2025. Sales rose 4.42% to Rs 8751.50 crore in the quarter ended March 2026 as against Rs 8381.12 crore during the previous quarter ended March 2025. For the full year,net profit rose 0.54% to Rs 3504.75 crore in the year ended March 2026 as against Rs 3485.88 crore during the previous year ended March 2025. Sales rose 6.39% to Rs 33384.74 crore in the year ended March 2026 as against Rs 31378.13 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales8751.508381.12 4 33384.7431378.13 6 OPM %20.0021.00 -20.5120.88 - PBDT1769.181779.52 -1 6955.376715.71 4 PBT1290.611335.09 -3 5177.185066.29 2 NP921.26903.47 2 3504.753485.88 1 Powered by Capital Market - Live

Aurobindo Pharma Ltd is up for a third straight session today. The stock is quoting at Rs 1541.4, up 1.57% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.12% on the day, quoting at 23630.9. The Sensex is at 75137.86, down 0.24%. Aurobindo Pharma Ltd has gained around 8.46% in last one month. Meanwhile, Nifty Pharma index of which Aurobindo Pharma Ltd is a constituent, has gained around 10.58% in last one month and is currently quoting at 24843.15, down 0.04% on the day. The volume in the stock stood at 4.58 lakh shares today, compared to the daily average of 12.95 lakh shares in last one month. The benchmark May futures contract for the stock is quoting at Rs 1540, up 1.34% on the day. Aurobindo Pharma Ltd is up 29.73% in last one year as compared to a 3.98% slide in NIFTY and a 15.38% slide in the Nifty Pharma index.The PE of the stock is 41.12 based on TTM earnings ending December 25.Powered by Capital Market - Live

Aurobindo Pharma announced that CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma, announced that the Central Drugs Standard Control Organization (CDSCO) has granted Marketing Authorisation under Form CT 23 for Bevqolva', a bevacizumab biosimilar indicated for metastatic carcinoma of the colon or rectum. The authorisation permits manufacture at CuraTeQ's facility in Hyderabad and marketing of Bevqolva' in 100 mg/4mL and 400 mg/16 mL vial presentations.

Aurobindo Pharma Ltd is up for a third straight session in a row. The stock is quoting at Rs 1514.7, up 1.15% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 1.27% on the day, quoting at 23710.55. The Sensex is at 75385.46, up 1.04%. Aurobindo Pharma Ltd has risen around 10.25% in last one month. Meanwhile, Nifty Pharma index of which Aurobindo Pharma Ltd is a constituent, has risen around 9.11% in last one month and is currently quoting at 23896.05, up 2.44% on the day. The volume in the stock stood at 7.76 lakh shares today, compared to the daily average of 14.11 lakh shares in last one month. The benchmark May futures contract for the stock is quoting at Rs 1522.1, up 1.16% on the day. Aurobindo Pharma Ltd is up 24.47% in last one year as compared to a 5.39% drop in NIFTY and a 13.06% drop in the Nifty Pharma index.The PE of the stock is 40.57 based on TTM earnings ending December 25.Powered by Capital Market - Live